SEC Form 4 · accession 0001190725-17-000122
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — President & CEO · Director
Period of report
May 9, 2017
Accepted (ET)
May 11, 2017 · 7:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Grant (Right to Buy)F1 | $8.49 | May 9, 2017 | D | 167,204 | D | Nov 13, 2013 | Nov 12, 2017 | Common Stock | 167,204 | 0 | D |
| Option Grant (Right to Buy)F1,F2 | $8.49 | May 9, 2017 | A | 167,204 | A | May 9, 2017 | Nov 12, 2022 | Common Stock | 167,204 | 167,204 | D |
Explanation of responses
- F1The two reported transactions involved i) a cancellation of a fully vested, five-year maximum term option which was granted to the reporting person on November 13, 2012 and ii) a grant of an option to the reporting person on May 9, 2017 pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan with the same exercise price and number of shares subject to the cancelled option. The new option is fully vested and has a maximum term of ten years from the November 13, 2012 grant date of the cancelled stock option.
- F2100% Fully Vested on the date of Grant.